State coverage
Idaho
Medicaid, for obesity: Does not cover. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- No anti-obesity drug appears on the current statewide list; the diabetes GLP-1s are covered for diabetes only.
Idaho runs a single, statewide fee-for-service pharmacy benefit through Prime Therapeutics — as of this read, the state was still surveying members and providers about a future shift to managed care, not operating one yet — so its Preferred Drug List is the one document that answers this question for essentially every Idaho Medicaid member, not one of several competing plan formularies.
That list, current as of September 1, 2026 for a July 1, 2026 effective date, has a GLP-1 class with exactly the drugs you'd expect for diabetes — Ozempic, Trulicity and Victoza preferred; Mounjaro, Byetta, Bydureon, Xultophy and Soliqua non-preferred, each gated behind a type 2 diabetes diagnosis code — and nothing else. Wegovy, Zepbound and Saxenda do not appear anywhere in the 42-page combined drug-list-and-criteria document, under any name, tier or footnote.
That absence is not backed by a named regulatory exclusion the way Alaska's is. Idaho's own excluded-drug-products rule lists fertility agents, cosmetic and hair-growth agents, cough-and-cold symptom relievers, and erectile-dysfunction agents by name — weight-loss or anti-obesity agents are not on that list. The state's coverage decision here appears to live entirely in what its Pharmacy and Therapeutics Committee has and hasn't added to the drug list, not in a written exclusion; the list's own front matter notes that any newly launched drug starts non-preferred "until reviewed by the Department of Health and Welfare Pharmacy and Therapeutics committee," though that alone would not explain a drug approved as far back as 2021 (Wegovy) never appearing at all.
We also checked the state's 196-page Medical Services provider handbook, which covers bariatric surgery for weight loss in detail but does not mention any GLP-1 drug by name, and the Department's Pharmacy and Therapeutics Committee page, which carries no GLP-1 or obesity-specific content as of this read.
What we could verify for Idaho
The state's current GLP-1 class covers diabetes only, by diagnosis code, and lists no anti-obesity brand: "HYPOGLYCEMICS, INCRETIN MIMETICS... Glucagon-like Peptide-1 (GLP-1) Receptor Agonists... Preferred Agents: OZEMPIC pen (semaglutide), TRULICITY (dulaglutide), VICTOZA (liraglutide)... Non-Preferred Agents: BYDUREON BCISE (exenatide), BYETTA (exenatide), exenatide pen, liraglutide, MOUNJARO (tirzepatide), OZEMPIC tablet (semaglutide)... SOLIQUA... XULTOPHY... Criteria for Preferred Agent: ICD-10 diagnosis of type 2 diabetes mellitus in member's record or submitted with pharmacy claim."
Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 2026 · source
The state's general excluded-drug regulation names four specific categories, and weight loss is not one of them: "Idaho Medicaid excludes from coverage the following drugs or classes of drugs... a. Agents, when used to promote fertility. b. Agents, when used for cosmetic purposes or hair growth. c. Agents, when used for the symptomatic relief of cough and colds... e. Agents, when used for the treatment of sexual or erectile dysfunction, unless such agents are used to treat a condition, other than sexual or erectile dysfunction, for which the agents have been approved by the Food and Drug Administration."
Idaho Administrative Code, IDAPA 16.03.09.662 (Prescription Drugs: Coverage and Limitations), effective March 2022 · source
The same drug list explains why a newly launched drug can be missing from a class without a formal exclusion: "Agents that are new to the market will be non-preferred until reviewed by the Department of Health and Welfare Pharmacy and Therapeutics committee." The list gives no indication such a review has happened for any anti-obesity GLP-1.
Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 2026 · source
Idaho gives Medicaid members 28 days to appeal a coverage decision: "If the department makes a decision about the Medicaid services and benefits you receive... and you disagree with that decision, or you believe the amount of benefit you receive is incorrect, you have the right to file an appeal. You have 28 days from the date on your notice about the decision to file an appeal about Medicaid services."
Idaho Department of Health and Welfare, Appeals and Fair Hearings · source
Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.
If the appeal fails, or you cannot wait
Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| CoreAge RxCheck availability | Advertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable. |
| OakCheck availability | Flat price across doses, free shipping with supplies. |
| Care Bare RxCheck availability | Names its pharmacies with addresses; sells brand Ozempic as well as compounded. |
| Gala HealthCheck availability | All doses one price, but the advertised rate needs a yearly subscription. |
| Synergy RxCheck availability | Providers licensed in your state; publishes no GLP-1 price before the consult. |
| Breeze MedsCheck availability | Serves all 50 states; publishes a starting price only. |
| Direct MedsCheck availability | No monthly membership, and one price at every dose. The lander our link opens starts at $147 and reads its own discount two ways on the same screen: the banner across the top says $150 off, the product tiles below it say up to $200 off. |
| FoundCheck availability | Bills the clinical visits through insurance where it is in network, with the medication charged separately. Read its Medicare Part D route closely: it advertises brand GLP-1s from $50 a month, and the footnote under that offer says the $50 does not count toward your Part D deductible or out-of-pocket maximum, and that Extra Help does not apply. |
| EdenCheck availability | Two different prices for the same drug depending on which door you come in. The lander our link opens advertises $99 a month for semaglutide, held at every dose, with no membership fee. Eden's own weight-loss page, read the same day, offers it from $99 a month plus an Eden Membership, and the footnote there says the membership is $39 the first month and $99 after, and that medication is not available without one. |
| ShedRxCheck availability | Publishes no price before the questionnaire: you answer it, pick a plan and see the cost at checkout. Sells injections plus needle-free drops and lozenges, and a footnote on the same page names sixteen states where the oral forms are not available. |
| TrimiCheck availability | Compounded tirzepatide at $125 a month and semaglutide at $99, each on the annual plan and each the same price at every dose. One membership covers the medication, the clinician visits and shipping. |
| He & She MDCheck availability | Advertises semaglutide from $99 a month and charges only if a prescription is written. The printed tiers are higher than the headline: $139 a month on six months, billed $834 at once, and $149 a month on three. GLP-1s ship to every state except Louisiana. |
| HealthRXCheck availability | Compounded semaglutide from $133 a month on a three-month plan and as low as $99 on twelve; tirzepatide from $209, as low as $179. ⚠ The page states its member reviews are illustrative composites rather than real patients. |
| Pallas HealthCheck availability | Compounded semaglutide at $139 for the first month and then $597 every twelve weeks, and tirzepatide at $179 then $897. ⚠ The page discloses that some of its content is AI-generated and that its imagery uses models rather than patients. |
| MEDGmCheck availability | GLP-1 injections from $179 and tablets from $249, with brand-name options priced as a membership plus the cost of the drug — $99 for Zepbound or Wegovy, $171 for Ozempic. ⚠ It discloses AI-generated content and actor imagery beside more than twenty named patient testimonials. |
| Bodybuilding Health+Check availability | Compounded tirzepatide runs $174.67 to $209 a month depending how many months are bought at once, and semaglutide is tiered the same way. ⚠ The program is listed as Bodybuilding.com; the page this link opens brands itself Bodybuilding Health+ and is operated by Dynamo Group LLC. |
| Strut HealthCheck availability | A multi-category telehealth storefront — sexual health, testosterone, hair, skin, peptides, menopause — where weight loss is one tile among six. It publishes no price for a GLP-1, or for anything else, on the page this link opens. |
| RxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing and no hidden fees, and then publishes no price at all — not for a GLP-1 and not for any other product — on the page this link opens. |
Prices in those notes were read from each company's own site in August 2026 and September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Idaho Department of Health and Welfare, Idaho Medicaid Preferred Drug List with Prior Authorization Criteria, effective July 2026 — publicdocuments.dhw.idaho.gov/WebLink/0/edoc/15075/PDL.pdf
- Idaho Administrative Code, IDAPA 16.03.09.662 (Prescription Drugs: Coverage and Limitations), effective March 2022 — www.law.cornell.edu/regulations/idaho/IDAPA-16.03.09.662
- Idaho Department of Health and Welfare, Appeals and Fair Hearings — healthandwelfare.idaho.gov/appeals-and-fair-hearings
Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.